COX2 inhibition may have antifibrotic effects in COVID-19 patients because epithelial–mesenchymal transition is a key evolutionary phenomenon in many physiologic and disease states of the lung, including lung development, chronic obstructive pulmonary disease (COPD), lung cancer, and pulmonary fibrosis [92,93]. This evidence concerns the gene PTGS2 and pulmonary fibrosis.